Prostate Cancer Recurrence After HIFU: Key Points

Prostate cancer recurrence after high-intensity focused ultrasound (HIFU) happens in a meaningful minority of men, with rates varying depending on whether the treatment targeted the whole gland or just the tumor. A recent meta-analysis found recurrence in about 15% of men after whole-gland HIFU and roughly 24% after focal HIFU, though individual studies report ranges as wide as 5% to 29% depending on how recurrence is measured and where in the prostate it appears. Understanding what drives those numbers, how recurrence is caught, and what can be done about it is where the picture gets genuinely useful.

How Often Does Cancer Come Back After HIFU

The recurrence rate you see depends heavily on two things: how much of the prostate was treated and where the cancer reappears. Focal HIFU, which targets only the known tumor area, carries a higher recurrence rate than whole-gland treatment. A 2025 systematic review and meta-analysis across multiple studies found whole-gland HIFU had a recurrence rate of about 15%, compared with roughly 24% for focal approaches. Post-treatment PSA levels reflected the same gap, averaging 0.68 ng/mL after whole-gland treatment and 2.81 ng/mL after focal HIFU.¹

That difference makes intuitive sense. Focal treatment intentionally leaves untreated prostate tissue behind, and that tissue can harbor cancer that was either missed on pre-treatment imaging or develops independently. A systematic review of focal HIFU studies that used both MRI and follow-up biopsies found that clinically significant cancer within the treated zone recurred in 5% to 22% of men, while new or progressive cancer outside the treated zone appeared in 2% to 29%.² The wide spread in those ranges reflects differences in patient selection, follow-up length, and biopsy protocols across studies. Still, the general picture is clear: after focal HIFU, you can have recurrence right where the cancer was treated, or you can have new trouble elsewhere in the gland.

What “Recurrence” Actually Means After HIFU

Defining recurrence after HIFU is less straightforward than you might expect. After radical prostatectomy, the prostate is gone, so any detectable PSA signals a problem. After HIFU, healthy prostate tissue remains and continues producing PSA, which means doctors have to figure out whether a rising PSA reflects returning cancer or just normal prostate activity. Several competing definitions exist, and which one a clinic uses can change whether you are told your cancer has come back.

Two of the most commonly referenced definitions both work off the idea of a PSA “nadir,” meaning the lowest PSA level you reach after treatment. The Phoenix definition flags recurrence when PSA rises more than 2 ng/mL above nadir. The Stuttgart definition uses a tighter threshold of nadir plus 1.2 ng/mL.³ A more recently studied set of criteria uses time-sensitive thresholds: a PSA rise of 1.0 ng/mL over nadir within the first twelve months, or a rise of 1.5 ng/mL over nadir between twenty-four and thirty-six months, should raise suspicion.⁴ Researchers have tested these definitions head-to-head to see which best predicts actual cancer on follow-up biopsy, and the answer is still evolving.⁵

The practical consequence for you: if your PSA starts climbing after HIFU, it does not automatically mean cancer is back. But it does mean your doctors will want to investigate further with imaging and possibly a biopsy. The threshold at which they act may differ depending on your center’s preferred definition.

Which Factors Predict a Higher Chance of Recurrence

Not every man who undergoes HIFU faces the same odds of recurrence. Several pre-treatment characteristics have emerged as strong predictors, and they matter for understanding whether HIFU is the right fit in the first place.

The most consistently identified risk factors are the aggressiveness of the original cancer and how low PSA drops after treatment. One study found that men with a Gleason score of 7 or higher before treatment had nearly three times the risk of biochemical recurrence, and men with stage T2b or higher disease had a similarly elevated hazard. The PSA nadir itself turned out to be the strongest independent predictor: men whose PSA dropped below about 0.43 ng/mL had dramatically better outcomes than those whose nadir stayed above that level, with a more than seven-fold difference in recurrence risk.⁶

An earlier study underscored the same point from a different angle. It sorted men into three groups based on how low their PSA fell and tracked failure rates over five years. Men with the lowest PSA nadirs had a five-year disease-free survival of 95%, while those in the middle group were at 55%, and men with higher nadirs had a 0% five-year disease-free survival rate.⁷ The PSA nadir is usually reached within about six months of HIFU, so it becomes a useful early signal of how well treatment worked.

More recent data has added genomic risk scoring to the picture. A 2025 study of 135 men who underwent biopsy at twelve months found that both higher-grade disease (Gleason grade group 3 or above) and a high genomic risk score were independently linked to in-field recurrence. Pre-treatment PSA above 10 ng/mL was also associated with a roughly five-fold increase in overall biopsy-proven recurrence compared to men with PSA below 6.⁸ This suggests that as genomic testing becomes more widely used, it may help clinicians identify men who are less likely to do well with HIFU and steer them toward other options upfront.

Detecting Recurrence With Imaging

After HIFU, the treated area of the prostate looks different on imaging than normal prostate tissue, which complicates the job of spotting returning cancer. MRI and PSMA PET scans both play a role, but each has real limitations that anyone in post-HIFU surveillance should know about.

MRI After HIFU

Multiparametric MRI is the standard imaging tool after HIFU, but its accuracy for detecting clinically significant recurrence is far from perfect. A systematic review and meta-analysis of MRI performance after focal HIFU found that pooled sensitivity was only about 52%, meaning MRI missed roughly half of clinically significant recurrences. Specificity was better at around 81%, and the negative predictive value was about 82%.⁹ In plain terms, a clean MRI after focal HIFU is reassuring but does not rule out recurrence. About one in five men with a negative MRI may still have significant cancer.

A separate study evaluating post-ablation MRI found a related problem from the other direction. Among men who did have persistent significant cancer on biopsy, 58% had no visible lesion on MRI at all. And among men whose MRI did flag a suspicious area, half of those turned out to have either no cancer or only low-grade disease on biopsy.¹⁰ The post-treatment scarring, inflammation, and tissue changes from HIFU can mimic cancer on imaging or hide it entirely. This is why most expert centers do not rely on MRI alone for surveillance after focal treatment.

PSMA PET Scans

PSMA PET imaging offers a different approach. Instead of looking at tissue structure the way MRI does, it uses a radioactive tracer that binds to a protein found on prostate cancer cells. In men with biochemical recurrence after HIFU, a single-center retrospective study found that PSMA PET identified a site of recurrence in about 64% of patients. Of those with positive scans, half had local recurrence in the prostate, while smaller numbers showed disease in pelvic lymph nodes or distant metastases.¹¹ A larger study of 112 patients found PSMA PET was positive in 82% of men on a per-patient basis, with intraprostatic uptake being the most common finding, followed by suspected seminal vesicle invasion in about a quarter and pelvic lymph node involvement in 15%.¹²

Neither MRI nor PSMA PET is clearly superior to the other when used alone. One study that compared both head-to-head found that sensitivity was 72% for PSMA PET and 76% for MRI, with identical specificity of about 83%. But when the two were used together, sensitivity jumped to 92% and overall accuracy rose to about 87%, at the cost of slightly lower specificity.¹³ The emerging consensus is that combining both modalities catches the most recurrences, though this paired approach adds cost and is not yet standard at most centers.

The Role of PSA Monitoring and Biopsies

Given the imaging limitations, PSA monitoring remains the backbone of post-HIFU surveillance. Tracking how PSA changes over time, rather than relying on a single reading, appears to provide better predictive value for recurrence. A study evaluating various surveillance strategies concluded that “for cause” biopsies triggered by dynamic PSA changes combined with MRI appeared to enhance recurrence detection without missing a significant number of cases.¹⁴ In practice, this means regular PSA checks, imaging when the numbers look concerning, and targeted biopsies when both point toward trouble. The absence of a standardized follow-up protocol remains one of the biggest gaps in focal therapy, with expert centers largely relying on their own institutional experience rather than unified guidelines.¹⁵

Treatment Options When Cancer Recurs

One of the arguments in favor of HIFU, particularly focal HIFU, is that it preserves future treatment options. If cancer does come back, several salvage treatments are available. Each comes with trade-offs.

Salvage Radical Prostatectomy

Removing the prostate entirely after failed HIFU is technically feasible, but the surgery is harder than a first-time prostatectomy. A systematic review and meta-analysis of salvage radical prostatectomy after focal ablation found that complication rates and cancer control were acceptable, but functional outcomes were suboptimal compared to men having surgery as a first treatment.¹⁶ A study of robotic salvage prostatectomy after HIFU partial ablation illustrated the functional toll: while about two-thirds of men were pad-free a year after surgery, potency rates dropped to zero at both three and twelve months. More than half of the surgical specimens showed aggressive disease, and nearly two-thirds had cancer extending outside the prostate.¹⁷ These numbers highlight a real tension: by the time cancer recurs and gets caught, it may have progressed enough that salvage surgery, while effective for cancer control, comes with a heavier functional price than the original HIFU was trying to avoid.

Salvage Radiation Therapy

Radiation after failed HIFU is another option and appears to be well tolerated. A small but notable study of eight men who received radiation for local recurrence after HIFU reported that all experienced significant PSA declines, with no biochemical failures over a median follow-up of more than six years. Toxicity was manageable, with no severe side effects reported.¹⁸ A larger multicenter study of 56 men treated with volumetric modulated arc therapy after HIFU failure similarly found no biochemical, local, or distant relapses over a median follow-up of about 20 months, with toxicity largely limited to grade 2 or lower urinary and gastrointestinal symptoms.¹⁹ These are early and small datasets, but they suggest radiation can be an effective and reasonably gentle salvage approach for local recurrence after HIFU.

Repeat HIFU or Other Focal Treatments

In selected cases, a second round of HIFU or another focal treatment can be considered, particularly if recurrence is localized and low-volume. This approach preserves the organ-sparing philosophy of the original treatment. However, repeat treatment is most suitable for men with clearly defined, accessible lesions rather than diffuse recurrence throughout the gland.

Long-Term Cancer Outcomes

Given the recurrence rates discussed above, an obvious question is whether HIFU still provides good long-term cancer control despite some men needing additional treatment. The longest follow-up data available come from a study tracking outcomes over 21 years after whole-gland HIFU. At 15 years, cancer-specific survival rates were 95% for men who started with low-risk disease, 89% for intermediate-risk, and 65% for high-risk. Metastasis-free survival at 15 years followed a similar pattern: 91% for low-risk, 85% for intermediate-risk, and 58% for high-risk. Freedom from any salvage treatment (including repeat HIFU) was lower across all groups, reflecting the fact that many men needed further intervention over time.²⁰

The data suggests that for men with low- and intermediate-risk prostate cancer, HIFU provides strong long-term cancer-specific survival even when some require retreatment. High-risk patients fare considerably worse, which is consistent with guidelines that generally recommend HIFU for low- and intermediate-risk disease rather than aggressive cancers.

For salvage HIFU specifically, meaning HIFU used to treat men whose cancer has come back after radiation, a multi-institutional study of 418 patients reported seven-year overall survival of 72%, cancer-specific survival of 82%, and metastasis-free survival of 81%.²¹ Those numbers are encouraging for a salvage setting, though the procedure comes with significant morbidity.

Quality of Life After Recurrence and Salvage Treatment

One of the main reasons men choose HIFU in the first place is to preserve urinary and sexual function. When recurrence forces a salvage treatment, some of those gains can be lost, and the degree depends on what salvage approach is used.

After salvage HIFU for cancer that recurred following radiation, a study found that urinary function scores declined from about 80 to 67, and sexual function scores dropped from around 32 to 17. Bowel function was unaffected, and mental health scores remained stable, but the physical impacts on urinary and sexual function were significant.²² A more recent study of salvage HIFU after radiation found that severe incontinence rates increased from 7% to 12%, though overall quality-of-life scores on a validated questionnaire showed no deterioration at twelve months.²³

These quality-of-life findings illustrate a pattern worth understanding: salvage HIFU tends to affect urinary and sexual function while leaving bowel function and general mental well-being relatively intact. Salvage surgery, as described earlier, carries even heavier functional costs, particularly for potency. Salvage radiation after HIFU appears to have the mildest side-effect profile based on available data, though the datasets are still small. The choice among salvage options often comes down to balancing cancer control against the functional domains that matter most to the individual patient.

The Role of Genomic Testing

Genomic classifiers are increasingly used in prostate cancer management after surgery or radiation, and their role after HIFU is beginning to take shape. Guidelines from major oncology organizations recommend genomic testing as part of building a patient’s overall risk profile for recurrence. Post-surgery genomic tests that analyze the expression of multiple genes have been shown to independently predict biochemical failure, distant metastasis, and cancer-specific death beyond what standard clinical features alone can provide.²⁴

The 2025 study mentioned earlier that found a high genomic risk score was independently linked to in-field recurrence after HIFU represents an early but promising application of these tools to the focal therapy setting.⁸ If validated more broadly, genomic testing could help divide men into those for whom HIFU is likely to provide durable control and those who would benefit from more aggressive initial treatment. For men who have already undergone HIFU and face recurrence, genomic information from the recurrent tumor may also guide whether salvage treatment should be local or systemic, though this particular application is still in early investigation.

Why There Is No Standard Follow-Up Protocol

One of the more frustrating realities for men who have had HIFU is that no evidence-based, standardized follow-up schedule exists. A comprehensive review noted that expert centers largely rely on their own institutional protocols rather than unified guidelines.¹⁵ This means the frequency of PSA checks, the timing of post-treatment MRI, whether routine biopsies are performed at a set interval or only when triggered by PSA changes, and the criteria for declaring recurrence can all differ depending on where you were treated.

The lack of consensus reflects the relative newness of focal therapy in prostate cancer and the multiple competing definitions of biochemical recurrence described earlier. It also stems from the imaging challenges: when MRI misses half of significant recurrences, a surveillance protocol built around routine MRI alone is going to have gaps. Some centers biopsy every man at twelve months regardless of imaging findings, while others reserve biopsy for men whose PSA trajectory or MRI raises concern. Both approaches have defenders, and both have trade-offs in terms of catching recurrences versus subjecting men to unnecessary procedures. For patients, the practical takeaway is to ask your treatment center to explain their specific follow-up plan, how often PSA will be checked, when imaging is scheduled, and under what circumstances a biopsy would be recommended.